Xploration of bio-mediators in pediatric neurocritical care and rewarding that right after

Xploration of bio-mediators in pediatric neurocritical care and rewarding that just after over 15 years of work in this region, use of those tools may perhaps come to be standardized and incorporated into routine clinical use for diagnosis, prognosis as well as other elements of patient management. Assessment of bio-mediators and biomarkers in CSF and serum is also helping to define therapeutic targets and give theragnostic value in monitoring treatment efficacy. Brain injury biomarkers could also guide patient stratification for clinical trials ?to help define the top sample for future RCTs or assist show therapy effects. This may be important provided the a lot of failures of trials in TBI along with the heterogeneity of this as well as other conditions in pediatric neurocritical care. We look forward towards the development of point of care technologies for brain injury biomarker applications in pediatric neurocritical care. ACKNOWLEDGMENTS Dr. Kochanek is supported by W81XWH-10-1-0623 in the US Army. We also thank NIH for help, specifically, K23 NS065132 (Ericka L. Fink), HD 055986 (Rachel P. Berger), NS038620 and HD045968 (Robert S. B. Clark), and NS061817 and HD057587 (H ya Bayir). We thank Marci Provins and Natalie Nieman for preparation with the manuscript.Frontiers in Neurology | NeurotraumaApril 2013 | Volume 4 | Article 40 |Kochanek et al.Biomarkers in pediatric brain injury
Int. J. Mol. Sci. 2013, 14, 8948-8962; doi:ten.3390/ijmsOPEN ACCESSInternational Journal ofMolecular SciencesISSN 1422-0067 mdpi/journal/ijms ArticleNew Radioligands for Describing the Molecular Pharmacology of MT1 and MT2 Melatonin ReceptorsC ine Legros 1, Ulrich Matthey 2, Teresa Grelak two, Sandrine Pedragona-Moreau three, Werner Hassler 4, Sa Yous 5, Emmanuel Thomas 6, Franck Suzenet 7, Beno Folleas six, Fran is Lefoulon 3, Pascal Berthelot five, Daniel-Henri Caignard 8, G ald Guillaumet 7, Philippe Delagrange eight, Jean-Louis Brayer six, Olivier Nosjean 1 and Jean A.Fmoc-Dab(Alloc)-OH site Boutin 1,*BPMC, Institut de Recherches SERVIER, 125 chemin de Ronde, Croissy-sur-Seine 78290, France; E-Mails: celine.3-Bromoquinolin-5-ol supplier legros@fr.PMID:23453497 netgrs (C.L.); [email protected] (O.N.) Celerion Switzerland AG Allmendstrasse 32, Fehraltorf CH-8320, Switzerland; E-Mails: Ulrich.matthey@celerion (U.M.); teresa.grelak@celerion (T.G.) Technologie SERVIER, 27 rue Vignat, Orl ns 45000, France; E-Mails: [email protected] (S.P.-M.); [email protected] (F.L.) ANAWA Trading SA, Unterdorfstrasse 21, Wangen CH-8602, Switzerland; E-Mail: [email protected] Universit?Lille Nord de France, F-59000 Lille, France UDSL, EA GRIIOT, UFR Pharmacie, Lille F-59000, France; E-Mail: [email protected] (S.Y.); [email protected] (P.B.) DIVERCHIM, six Rue du Noyer, Roissy 95700, France; E-Mails: emmanuel.thomas@diverchim (E.T.); benoit.folleas@diverchim (B.F.); [email protected] (J.-L.B.) Institut de Chimie Organique et Analytique, UMR CNRS 7311, Universit?d’Orl ns, rue de Chartres, Orl ns 45067, France; E-Mails: [email protected] (F.S.); [email protected] (G.G.) Unit?de Recherches et D ouvertes en Neurosciences, Institut de Recherches SERVIER, 125 chemin de Ronde, Croissy-sur-Seine 78290, France; E-Mails: [email protected] (D.-H.C.); [email protected] (P.D.)* Author to whom correspondence really should be addressed; E-Mail: [email protected]; Tel.: +33-0155-722-748; Fax: +33-0155-722-810. Received: 16 March 2013; in revised type: 14 April 2013 / Accepted: 15 April 2013 / Published: 25 Apr.